Application of rhynchophylline in preparation of medicine for treating inflammatory enteritis

A technology for inflammatory bowel disease and rhynchophylline, which is applied in the field of application of rhynchophylline in the preparation of drugs for treating inflammatory bowel disease, can solve problems such as restriction, drug allergy-dependent drug resistance, liver and kidney function damage, etc., and achieve the reduction of intestinal mucosa Permeability, effect of promoting intestinal barrier integrity

Pending Publication Date: 2022-07-08
XINJIANG MEDICAL UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Sulfasalazine was once used as a first-line drug for the treatment of IBD, but its clinical application was gradually limited due to adverse reactions such as allergic reactions and liver and kidney dysfunction
Although aminosalicylic acid, glucocorticoids, immunosuppressants, and biological agents can relieve the symptoms of IBD, the condition of IBD is changing dynamically, and drug allergy, drug dependence, drug resistance, and even drug ineffectiveness are inevitable during the long course of medication However, there are still many problems to be solved in the field of IBD treatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of rhynchophylline in preparation of medicine for treating inflammatory enteritis
  • Application of rhynchophylline in preparation of medicine for treating inflammatory enteritis
  • Application of rhynchophylline in preparation of medicine for treating inflammatory enteritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] (1) Animal grouping and administration

[0033] 60 C57 / BL6j mice aged 6-7 weeks and weighing 18-22g were divided into control group, positive drug group, model group, and urticine (low, medium and high) dose groups, with 10 mice in each group. The mice in the control group were given normal diet and drinking water every day without treatment. Mice in the model group, urticine (low, medium, high) group and positive drug group freely drank 2% DSS (dextran sodium sulfate) solution instead of drinking water and ate freely every day. The mice in the control group and the model group were given 0.1ml / 10g body weight of sterile water by gavage every day, and the rhynchophylline (low, medium, and high) groups were respectively given an aqueous solution of rhynchophylline (2mg / kg in the low-dose group and 4mg in the middle-dose group). / kg, high-dose group 8 mg / kg) once a day for 7 consecutive days. The positive drug group was injected intraperitoneally with dexamethasone 0.00...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of rhynchophylline in preparation of a medicine for treating inflammatory enteritis. The invention firstly finds that the rhynchophylline has a repairing effect on injury caused by inflammatory enteritis; research finds that rhynchophylline can significantly reduce the concentration of inflammatory factors in colon, protect colon tissue, repair intestinal barrier permeability and activate AhR, so that intestinal inflammation can be relieved, and the intestinal barrier permeability can be repaired. The invention provides an application prospect of rhynchophylline in preparation of medicines for treating inflammatory enteritis.

Description

technical field [0001] The invention belongs to the technical field of drug application, and particularly relates to the application of urticine in the preparation of a drug for treating inflammatory bowel disease. Background technique [0002] In the past 20 years, the number of Inflammatory Bowel Disease (IBD) cases in my country has increased rapidly, with a prevalence rate of 0.24-0.34% and an annual mortality rate of 0.019-0.023%. It is estimated that by 2025, the number of IBD patients in China will reach 1.5 million. IBD has a long course of disease, with recurrent symptoms. Most of the patients are under the age of 30. The long-term disease leads to emotional anxiety, depression, and inability to sleep and play normally. Due to long-term repeated inflammation, IBD evolves into colon cancer. According to statistics, the risk of colon cancer in IBD is 2-4 times that of the normal population. [0003] At present, the drug treatment of IBD mainly focuses on local inte...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/438A61K36/74A61P1/00A61P29/00A61P3/00
CPCA61K31/438A61K36/74A61P1/00A61P29/00A61P3/00
Inventor 毛旭文程路峰杨浩阿米尔·泽布古丽若依·帕尔哈提张雍正刘宇
Owner XINJIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap